Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28576192 | 0.79 | TSHR (0.39) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL28873044 | 0.75 | GAA (0.39) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL5095243 | 0.75 | TSHR (0.41) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL3892858 | 0.75 | ALDH1A1 (0.45) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL21752027 | 0.74 | MME (0.34) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| Bromide SCHEMBL21752031 | 0.73 | MME (0.33) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL14165607 | 0.72 | ALDH1A1 (0.42) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL28815502 | 0.72 | ALDH1A1 (0.38) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| Benzene SCHEMBL28175146 | 0.72 | ALDH1A1 (0.42) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL1781639 | 0.71 | DPP4 (0.49) | TSHRUSP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264135-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-01 | — | — | US | disclosed |
| US-20240199556-A1 | Synthesis of 1,4-Diazaspiro[5.5]Undecan-3-One | G1 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-109789142-B | Synthesis of N- (heteroaryl) -pyrrolo [3,2-D ] pyrimidin-2-amines | G1治疗公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3840756-A1 | IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | G1 Therapeutics, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210179567-A1 | SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | G1 THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179567-A1 | SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | G1 THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| CN-112839657-A | Improved synthesis of 1, 4-diazaspiro [5.5] undecan-3-ones | G1治疗公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020041770-A1 | IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | G1 THERAPEUTICS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264135-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | NDC1, SDC1, SDC2 | TSHR 3147/4885USP2 1000/4885ALDH1A1 723/4885 |
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | NDC1, SDC1, SDC2 | TSHR 3147/4885USP2 1000/4885ALDH1A1 723/4885 |
| US-20210179567-A1 | SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | NDC1, SDC1, SDC2 | TSHR 3147/4885USP2 1000/4885ALDH1A1 723/4885 |
| US-20240199556-A1 | Synthesis of 1,4-Diazaspiro[5.5]Undecan-3-One | NDC1, SDC1, SDC2 | TSHR 3147/4885USP2 1000/4885ALDH1A1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.